Scopa James's Insider Trades & SAST Disclosures
Scopa James's most recent trade in Aligos Therapeutics Inc was a trade of 60,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 27, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Scopa James.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aligos Therapeutics Inc | James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Adverum Biotechnologies Inc | James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 10,520 | 10,520 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Scopa James | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Feb 2024 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Aligos Therapeutics Inc | Scopa James | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 8,823 | 8,823 | - | - | Stock Option (Right to Buy) | |
| Adverum Biotechnologies Inc | Scopa James | Director | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 07 Feb 2024 | 100,000 | 100,000 (0%) | 0% | 1.4 | 135,000 | Common Stock |
| Aligos Therapeutics Inc | James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2023 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Adverum Biotechnologies Inc | James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Adverum Biotechnologies Inc | James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Adverum Biotechnologies Inc | James Scopa | Director | Sale of securities on an exchange or to another person at price $ 2.18 per share. | 15 Nov 2021 | 50,000 | 3,334 (0%) | 0% | 2.2 | 109,000 | Common Stock |
| Adverum Biotechnologies Inc | James Scopa | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges